Semaglutide 0.5mg / 1mg / 2mg โ Weekly injection for Type 2 diabetes and weight loss
Ozempic (semaglutide) is a GLP-1 receptor agonist developed by Novo Nordisk. It mimics the naturally occurring GLP-1 hormone, which is released after eating. By activating GLP-1 receptors, Ozempic:
Ozempic was approved in India by CDSCO in September 2025 and officially launched by Novo Nordisk in December 2025. Novo Nordisk cut prices by 36% in April 2026 in response to Indian generic competition.
Prices reflect April 2026 Novo Nordisk price reduction. Always start at 0.25mg and escalate slowly.
| Dose | When | Per Week | Per Month | Purpose |
|---|---|---|---|---|
| 0.25mg | Weeks 1โ4 (starter) | โน708 | โน2,832 | Tolerance building โ no therapeutic effect |
| 0.5mg | Weeks 5โ8 | โน1,415 | โน5,660 | First therapeutic dose for diabetes |
| 1mg | Week 9 onwards | โน1,415 | โน5,660 | Standard maintenance dose |
| 2mg | If needed | โน2,000 | โน8,000 | Maximum dose for better glycaemic control |